Alliance's sobering budget analysis

Share this article:
FDA's drugs, biologics and medical devices programs are getting the shaft under the Obama administration's proposed FY 2011 budget request, according to an analysis by the Alliance for a Stronger FDA.

While the agency's new budget request seeks a 6% or $147 million increase in its appropriation, CDER and Center for Biologics Evaluation & Research would only be allotted a $28 million (4%) increase and 66 new positions, whereas devices would be given an $11 million increase (less than 4%) and 28 new positions.

“This is less than the cost of pay increases,” the group argues. “Other items that will increase this year (rent, information technology, training, travel) will need to come from existing program dollars.” The Alliance says the major problem with FDA's budget is that about 80% of the agency's costs each year are salary and people-related costs for benefits, rent, IT services, travel and training.

“If the FDA's appropriated budget does not grow by at least inflation each year, then staff levels decrease. This is what was happening for most years between 1994 and 2007. For example, after 9/11 the agency got significant new monies to hire new inspectors to decrease the risks of agro- and bio-terror. Within five years, this increase in the FDA field force had disappeared and the number of inspectors was about where it had been before the new
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.